Corneliu E. Giurgea

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Corneliu E. Giurgea (6 January 1923, Bucharest – 30 December 1995, Bruxelles)[1] was a Romanian psychologist and chemist. In 1964 he synthetised Piracetam, which he has described as a nootropic.[2]

Giurgea coined the term nootropic[3][4] in 1972.[5][6]

Nootropic characteristics[edit]

He stated that nootropic drugs should have the following characteristics:

  1. They should enhance learning and memory.
  2. They should enhance the resistance of learned behaviors/memories to conditions which tend to disrupt them (e.g. electroconvulsive shock, hypoxia).
  3. They should protect the brain against various physical or chemical injuries (e.g. barbiturates, scopalamine).
  4. They should increase the efficacy of the tonic cortical/subcortical control mechanisms.
  5. They should lack the usual pharmacology of other psychotropic drugs (e.g. sedation, motor stimulation) and possess very few side effects and extremely low toxicity.

Biography[edit]

He received a Ph.D. in medicine from the University of Bucharest, where he also taught for several years. He continued his research and specialisation in Psychology (doc) at the First Pavlov State Medical University of St. Peterburg, under some of Ivan Pavlov's closest collaborators such as Pyotyr Kupalov. He was then a post-doc at the University of Rochester and subsequently a professor at the Université catholique de Louvain and scientific counselor and researcher at the Belgian pharmaceutical company UCB.

Books and articles[edit]

Quotes[edit]

"Man is not going to wait passively for millions of years before evolution offers him a better brain."

References[edit]

  1. ^ Riga, Dan, Sorin Riga, Aurel Ardelean, and Coralia Cotoraci (2014-05-19). "Prof. Dr. Corneliu GIURGEA(1923 – 1995), descoperitorul Piracetamului şi al unei noi clase de medicamente în terapeutica mondială". Cover - Ultimul numar (in Romanian). Medica Academica. Retrieved 2014-06-30. 
  2. ^ Giurgea CE, Greindl MG, Preat S (1983). "Nootropic drugs and aging". Acta Psychiatr Belg 83 (4): 349–58. PMID 6660010. 
  3. ^ Shorvon S (December 2001). "Pyrrolidone derivatives". Lancet 358 (9296): 1885–92. doi:10.1016/S0140-6736(01)06890-8. PMID 11741647. 
  4. ^ "PHAR 402". 
  5. ^ Gazzaniga, Michael S. (2006). The Ethical Brain: The Science of Our Moral Dilemmas (P.S.). New York, N.Y: Harper Perennial. p. 184. ISBN 0-06-088473-8. 
  6. ^ Giurgea C (1972). "[Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology] ("Vers une pharmacologie de l'active integrative du cerveau: Tentative du concept nootrope en psychopharmacologie")". Actual Pharmacol (Paris) (in French) 25: 115–56. PMID 4541214.